JPMorgan Upgrades RAPT Therapeutics on Promising Drug Trial Results
JPMorgan raises RAPT stock rating to Overweight with $55 target after Phase 2 trial success. Stock jumps 17% on positive chronic urticaria treatment data.
/ 3 items
#RAPT↓
FDA Greenlights RAPT's Next-Gen Food Allergy Treatment Trial
FDA OKs major trial (prestIgE) for RPT904, a next-gen anti-IgE drug. It will treat ~100 people allergic to peanut, milk, or egg. The goal is a better, safe therapeutic option by blocking IgE, the key driver of these allergies.
Big Upgrade for Rapt Therapeutics’ Allergy Drug RPT904
Leerink Partners dramatically upgraded Rapt Therapeutics stock based on the strong outlook for RPT904, a leading drug candidate designed to treat severe allergies, including food allergy, by improving on the current standard treatment, Xolair.